US5994392A
(en)
|
1988-02-26 |
1999-11-30 |
Neuromedica, Inc. |
Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
|
US20030073642A1
(en)
*
|
1993-02-22 |
2003-04-17 |
American Bioscience, Inc. |
Methods and formulations for delivery of pharmacologically active agents
|
US5439686A
(en)
*
|
1993-02-22 |
1995-08-08 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
|
US20030068362A1
(en)
*
|
1993-02-22 |
2003-04-10 |
American Bioscience, Inc. |
Methods and formulations for the delivery of pharmacologically active agents
|
US20030133955A1
(en)
*
|
1993-02-22 |
2003-07-17 |
American Bioscience, Inc. |
Methods and compositions useful for administration of chemotherapeutic agents
|
US5972948A
(en)
*
|
1994-07-01 |
1999-10-26 |
Solvay Pharmaceuticals Gmbh |
Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
|
US6231888B1
(en)
|
1996-01-18 |
2001-05-15 |
Perio Products Ltd. |
Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
|
US5795909A
(en)
*
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
JP4172726B2
(ja)
*
|
1996-05-22 |
2008-10-29 |
ルイトポルド・ファーマシューティカルズ・インコーポレーテッド |
シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
|
US6576636B2
(en)
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
KR100330373B1
(ko)
*
|
1996-05-28 |
2002-11-07 |
주식회사한국신약 |
탁솔을 함유한 주사용 약제 조성물
|
US6440980B1
(en)
*
|
1996-09-17 |
2002-08-27 |
Avanir Pharmaceuticals |
Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
|
PL337033A1
(en)
*
|
1997-05-21 |
2000-07-31 |
Univ Leland Stanford Junior |
Composition for and methods of enhancing transport through permeable biological membranes
|
US8853260B2
(en)
*
|
1997-06-27 |
2014-10-07 |
Abraxis Bioscience, Llc |
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
ZA986614B
(en)
*
|
1997-07-25 |
1999-01-27 |
Gilead Sciences |
Nucleotide analog composition
|
WO1999013872A1
(fr)
|
1997-09-17 |
1999-03-25 |
Eisai Co., Ltd. |
Produits antimicrobiens
|
US20030095927A1
(en)
*
|
1997-10-01 |
2003-05-22 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
|
US20040136915A1
(en)
*
|
1997-10-01 |
2004-07-15 |
Dugger Harry A. |
Buccal, polar and non-polar spray containing atropine
|
US20040136914A1
(en)
*
|
1997-10-01 |
2004-07-15 |
Dugger Harry A. |
Buccal, polar and non-polar spray containing ondansetron
|
US7632517B2
(en)
*
|
1997-10-01 |
2009-12-15 |
Novadel Pharma Inc. |
Buccal, polar and non-polar spray containing zolpidem
|
US20050180923A1
(en)
*
|
1997-10-01 |
2005-08-18 |
Dugger Harry A.Iii |
Buccal, polar and non-polar spray containing testosterone
|
US20040136913A1
(en)
*
|
1997-10-01 |
2004-07-15 |
Dugger Harry A. |
Buccal, polar and non-polar spray containing sumatriptan
|
US20050287075A1
(en)
*
|
1997-10-01 |
2005-12-29 |
Dugger Harry A Iii |
Buccal, polar and non-polar spray or capsule containing drugs for treating pain
|
US20030077229A1
(en)
*
|
1997-10-01 |
2003-04-24 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
|
US20030077227A1
(en)
*
|
1997-10-01 |
2003-04-24 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
|
US20030095926A1
(en)
*
|
1997-10-01 |
2003-05-22 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
|
WO1999016417A1
(en)
*
|
1997-10-01 |
1999-04-08 |
Flemington Pharmaceutical Corporation |
Buccal, polar and non-polar spray or capsule
|
US20030185761A1
(en)
*
|
1997-10-01 |
2003-10-02 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating pain
|
US20030082107A1
(en)
*
|
1997-10-01 |
2003-05-01 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
|
US20050002867A1
(en)
*
|
1997-10-01 |
2005-01-06 |
Novadel Pharma Inc. |
Buccal, polar and non-polar sprays containing propofol
|
US20090162300A1
(en)
*
|
1997-10-01 |
2009-06-25 |
Dugger Iii Harry A |
Buccal, polar and non-polar spray containing alprazolam
|
US20040141923A1
(en)
*
|
1997-10-01 |
2004-07-22 |
Dugger Harry A. |
Buccal, polar and non-polar spray containing alprazolam
|
US20030077228A1
(en)
*
|
1997-10-01 |
2003-04-24 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
|
US20050281752A1
(en)
*
|
1997-10-01 |
2005-12-22 |
Dugger Harry A Iii |
Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
|
US20030095925A1
(en)
*
|
1997-10-01 |
2003-05-22 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
|
US20030190286A1
(en)
*
|
1997-10-01 |
2003-10-09 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
|
US20050163719A1
(en)
*
|
1997-10-01 |
2005-07-28 |
Dugger Harry A.Iii |
Buccal, polar and non-polar spray containing diazepam
|
US5977174A
(en)
*
|
1997-11-26 |
1999-11-02 |
Neuromedica, Inc. |
Cholinergic compositions and uses thereof
|
US5955459A
(en)
*
|
1997-11-26 |
1999-09-21 |
Neuromedica, Inc. |
Fatty acid-antipsychotic compositions and uses thereof
|
US6197764B1
(en)
|
1997-11-26 |
2001-03-06 |
Protarga, Inc. |
Clozapine compositions and uses thereof
|
US6153653A
(en)
*
|
1997-11-26 |
2000-11-28 |
Protarga, Inc. |
Choline compositions and uses thereof
|
EP0966974B1
(en)
*
|
1998-01-13 |
2004-12-01 |
Daiichi Suntory Pharma Co., Ltd. |
Antibacterial composition for topical administration containing faropenem
|
US6958148B1
(en)
*
|
1998-01-20 |
2005-10-25 |
Pericor Science, Inc. |
Linkage of agents to body tissue using microparticles and transglutaminase
|
UA65607C2
(uk)
*
|
1998-03-04 |
2004-04-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Фармацевтична композиція (варіанти) та спосіб її приготування
|
FI980901A
(fi)
*
|
1998-04-23 |
1999-10-24 |
Orion Yhtymae Oyj |
Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
|
EP2263660B1
(en)
*
|
1998-05-18 |
2017-09-27 |
Takeda Pharmaceutical Company Limited |
Orally disintegrable tablets
|
US7413759B2
(en)
*
|
1998-05-21 |
2008-08-19 |
Beech-Nut Nutrition Corporation |
Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
|
AU763309B2
(en)
*
|
1998-07-20 |
2003-07-17 |
Smithkline Beecham Corporation |
Bioenhanced formulations comprising eprosartan in oral solid dosage form
|
EP1561458B1
(en)
*
|
1998-07-28 |
2010-09-15 |
Takeda Pharmaceutical Company Limited |
Rapidly disintegrable solid preparation
|
US6699508B1
(en)
*
|
1998-08-10 |
2004-03-02 |
Asahi Kasei Pharma Corporation |
Sustained release oral preparations of fasudil hydrochloride
|
CA2346001C
(en)
*
|
1998-10-01 |
2003-12-30 |
Elan Pharma International, Limited |
Controlled release nanoparticulate compositions
|
US8236352B2
(en)
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
US20080213378A1
(en)
*
|
1998-10-01 |
2008-09-04 |
Elan Pharma International, Ltd. |
Nanoparticulate statin formulations and novel statin combinations
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
US20040013613A1
(en)
*
|
2001-05-18 |
2004-01-22 |
Jain Rajeev A |
Rapidly disintegrating solid oral dosage form
|
US6428814B1
(en)
*
|
1999-10-08 |
2002-08-06 |
Elan Pharma International Ltd. |
Bioadhesive nanoparticulate compositions having cationic surface stabilizers
|
US7521068B2
(en)
*
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
US6652864B1
(en)
|
1998-12-21 |
2003-11-25 |
Asilomar Pharmaceuticals, Inc. |
Compounds for intracellular delivery of therapeutic moieties to nerve cells
|
CA2361303C
(en)
*
|
1999-01-29 |
2007-11-20 |
Takeda Chemical Industries, Ltd. |
Punch for preparing tablets
|
US7235583B1
(en)
|
1999-03-09 |
2007-06-26 |
Luitpold Pharmaceuticals, Inc., |
Fatty acid-anticancer conjugates and uses thereof
|
CZ20013123A3
(cs)
*
|
1999-03-09 |
2002-03-13 |
Protarga, Inc. |
Konjugátový přípravek mastné kyseliny protirakovinné sloučeniny, souprava pro podávání a farmaceutický preparát
|
US6475984B2
(en)
*
|
1999-04-29 |
2002-11-05 |
The Nemours Foundation |
Administration of leptin
|
DE60040979D1
(de)
*
|
1999-05-07 |
2009-01-15 |
Wockhardt Ltd |
(s)-benzochinolizincarbonsäuren und ihre verwendung als antibakterielle mittel
|
AU4834200A
(en)
*
|
1999-05-10 |
2000-11-21 |
Protarga, Inc. |
Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
|
US6197337B1
(en)
*
|
1999-05-10 |
2001-03-06 |
Kenneth Weisman |
Therapeutic uses of abarelix
|
US7175855B1
(en)
*
|
1999-05-27 |
2007-02-13 |
Pfizer Inc. |
Ziprasidone suspension
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
US7229961B2
(en)
|
1999-08-24 |
2007-06-12 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into ocular tissues
|
US6669951B2
(en)
|
1999-08-24 |
2003-12-30 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into epithelial tissues
|
US6730293B1
(en)
|
1999-08-24 |
2004-05-04 |
Cellgate, Inc. |
Compositions and methods for treating inflammatory diseases of the skin
|
JP2003507438A
(ja)
|
1999-08-24 |
2003-02-25 |
セルゲイト, インコーポレイテッド |
オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強
|
EP1214067A1
(en)
*
|
1999-09-09 |
2002-06-19 |
EFA Sciences Llc |
Methods for treating cell proliferative disorders including cancer
|
US6426367B1
(en)
*
|
1999-09-09 |
2002-07-30 |
Efa Sciences Llc |
Methods for selectively occluding blood supplies to neoplasias
|
US6541508B2
(en)
|
1999-09-13 |
2003-04-01 |
Nobex Corporation |
Taxane prodrugs
|
US6380405B1
(en)
|
1999-09-13 |
2002-04-30 |
Nobex Corporation |
Taxane prodrugs
|
US6713454B1
(en)
*
|
1999-09-13 |
2004-03-30 |
Nobex Corporation |
Prodrugs of etoposide and etoposide analogs
|
JP4776843B2
(ja)
|
1999-10-01 |
2011-09-21 |
イムノゲン インコーポレーティッド |
免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
|
US6383511B1
(en)
*
|
1999-10-25 |
2002-05-07 |
Epicept Corporation |
Local prevention or amelioration of pain from surgically closed wounds
|
WO2001040177A2
(en)
*
|
1999-12-02 |
2001-06-07 |
Women And Infants Hospital |
Esters of vitamin d3 and uses thereof
|
US6638906B1
(en)
|
1999-12-13 |
2003-10-28 |
Nobex Corporation |
Amphiphilic polymers and polypeptide conjugates comprising same
|
US6380253B1
(en)
*
|
2000-01-05 |
2002-04-30 |
Efa Sciences Llc |
Method of stabilizing and potentiating the action of anti-angiogenic substances
|
WO2001052867A1
(en)
|
2000-01-19 |
2001-07-26 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Use of pentosan polysulfate to treat certain conditions of the prostate
|
AR030188A1
(es)
*
|
2000-02-02 |
2003-08-13 |
Univ Florida State Res Found |
Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos
|
US6649632B2
(en)
|
2000-02-02 |
2003-11-18 |
Fsu Research Foundation, Inc. |
C10 ester substituted taxanes
|
DE60138853D1
(de)
*
|
2000-02-02 |
2009-07-16 |
Univ Florida State Res Found |
C10-taxanester als antitumormittel
|
US6730691B1
(en)
|
2000-02-10 |
2004-05-04 |
Miles A. Galin |
Uses of alpha adrenergic blocking agents
|
US6660750B2
(en)
|
2000-02-15 |
2003-12-09 |
University Of Iowa Research Foundation |
Flavopiridol methods and compositions for HIV therapy
|
US6452024B1
(en)
|
2000-02-22 |
2002-09-17 |
Chaichem Pharmaceuticals International |
Process for extraction and purification of paclitaxel from natural sources
|
US20030083342A1
(en)
*
|
2002-08-27 |
2003-05-01 |
Steele Ronald Edward |
Combination of organic compounds
|
US20040156872A1
(en)
*
|
2000-05-18 |
2004-08-12 |
Elan Pharma International Ltd. |
Novel nimesulide compositions
|
US6392055B1
(en)
|
2000-07-19 |
2002-05-21 |
The University Of Pittsburgh |
Synthesis and biological evaluation of analogs of the antimitotic marine natural product curacin A
|
US7198795B2
(en)
*
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
US6884777B1
(en)
|
2000-11-14 |
2005-04-26 |
The Nemours Foundation |
Method for treating respiratory distress syndrome
|
WO2002076404A2
(en)
*
|
2001-03-23 |
2002-10-03 |
Protarga, Inc. |
Fatty alcohol drug conjugates
|
US8552054B2
(en)
*
|
2001-03-23 |
2013-10-08 |
Luitpold Pharmaceuticals, Inc. |
Fatty amine drug conjugates
|
US20020198228A1
(en)
*
|
2001-04-03 |
2002-12-26 |
Kaura Sita R. |
Composition and method for the treatment of respiratory desease
|
AU2002256471B2
(en)
*
|
2001-05-03 |
2007-05-24 |
Allergan, Inc. |
Compositions having enhanced pharmacokinetic characteristics
|
US20020198209A1
(en)
*
|
2001-05-03 |
2002-12-26 |
Allergan Sales Inc. |
Compositions having enhanced pharmacokinetic characteristics
|
US7425565B2
(en)
*
|
2002-05-09 |
2008-09-16 |
Cedars-Sinai Medical Center |
Use of benzothiopenes to treat and prevent prostate cancer
|
CA2354471A1
(en)
*
|
2001-07-31 |
2003-01-31 |
Florida State University Research Foundation, Inc. |
C10 ester substituted taxanes
|
CA2354486A1
(en)
*
|
2001-07-31 |
2003-01-31 |
Florida State University Research Foundation, Inc. |
C7 ester substituted taxanes
|
SG129990A1
(en)
*
|
2001-08-01 |
2007-03-20 |
Univ Florida State Res Found |
C10 ester substituted taxanes
|
SG125889A1
(en)
*
|
2001-08-01 |
2006-10-30 |
Univ Florida State Res Found |
C7 ester subsituted taxanes
|
US6852737B2
(en)
*
|
2001-08-06 |
2005-02-08 |
Recordati Ireland Limited |
Crude and crystalline forms of lercanidipine hydrochloride
|
ES2399977T3
(es)
*
|
2001-09-27 |
2013-04-04 |
Ramot At Tel Aviv University Ltd. |
Conjugado de perfenazina o flufenazina con ácidos carboxílicos
|
US7544681B2
(en)
|
2001-09-27 |
2009-06-09 |
Ramot At Tel Aviv University Ltd. |
Conjugated psychotropic drugs and uses thereof
|
AU2004201240B2
(en)
*
|
2001-09-27 |
2008-08-07 |
Bar Ilan University |
Conjugated Psychotropic Drugs and Uses Thereof
|
US6730667B2
(en)
*
|
2001-11-26 |
2004-05-04 |
William R. Deagle |
Iontophoresis disc pain blocker
|
EP1461033B1
(en)
*
|
2001-11-29 |
2013-02-27 |
Sound Pharmaceuticals Incorporated |
Methods and compositions for ameliorating the undesirable effects of chemotherapy
|
ES2497716T3
(es)
*
|
2002-01-04 |
2014-09-23 |
Sound Pharmaceuticals Incorporated |
Composiciones para utilizar en métodos destinados a tratar la pérdida auditiva
|
US20040101566A1
(en)
*
|
2002-02-04 |
2004-05-27 |
Elan Pharma International Limited |
Novel benzoyl peroxide compositions
|
CA2475092C
(en)
|
2002-02-04 |
2012-05-01 |
Christian F. Wertz |
Nanoparticulate compositions having lysozyme as a surface stabilizer
|
WO2003075741A2
(en)
*
|
2002-03-04 |
2003-09-18 |
Medimmune, Inc. |
METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
|
AU2003235931A1
(en)
*
|
2002-05-13 |
2003-11-11 |
Takata Seiyaku Co., Ltd. |
Vintoperol-containing medicinal composition for transdermal administration
|
US20040266776A1
(en)
*
|
2003-06-25 |
2004-12-30 |
Gil Daniel W. |
Methods of preventing and reducing the severity of stress-associated conditions
|
US20040002663A1
(en)
*
|
2002-06-26 |
2004-01-01 |
Reeves William H. |
Method and system for use in detecting a cancerous and precancerous pathology
|
JP4776229B2
(ja)
*
|
2002-07-16 |
2011-09-21 |
エラン ファーマ インターナショナル,リミティド |
安定なナノ粒子活性物質の液体投与組成物
|
US20040023935A1
(en)
*
|
2002-08-02 |
2004-02-05 |
Dey, L.P. |
Inhalation compositions, methods of use thereof, and process for preparation of same
|
US7273889B2
(en)
*
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
US20040235811A1
(en)
*
|
2002-10-08 |
2004-11-25 |
Sepracor Inc. |
Fatty acid modified forms of glucocorticoids
|
US20040109826A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Dey, L.P. |
Stabilized albuterol compositions and method of preparation thereof
|
US20040192581A1
(en)
*
|
2002-12-10 |
2004-09-30 |
Biosynexus Incorporated |
Topical anti-infective formulations
|
US7524515B2
(en)
*
|
2003-01-10 |
2009-04-28 |
Mutual Pharmaceuticals, Inc. |
Pharmaceutical safety dosage forms
|
JP2006515623A
(ja)
*
|
2003-01-13 |
2006-06-01 |
セダーズ−シナイ メディカル センター |
化学療法剤としてのパリカルシトール
|
US6759539B1
(en)
|
2003-02-27 |
2004-07-06 |
Chaichem Pharmaceuticals International |
Process for isolation and purification of paclitaxel from natural sources
|
US7811606B2
(en)
*
|
2003-04-16 |
2010-10-12 |
Dey, L.P. |
Nasal pharmaceutical formulations and methods of using the same
|
US8912174B2
(en)
|
2003-04-16 |
2014-12-16 |
Mylan Pharmaceuticals Inc. |
Formulations and methods for treating rhinosinusitis
|
US9808471B2
(en)
*
|
2003-04-16 |
2017-11-07 |
Mylan Specialty Lp |
Nasal pharmaceutical formulations and methods of using the same
|
NZ564694A
(en)
*
|
2003-04-22 |
2009-11-27 |
Sod Conseils Rech Applic |
Peptide vectors
|
PT1628685E
(pt)
|
2003-04-25 |
2011-03-16 |
Gilead Sciences Inc |
Análogos de fosfonatos antivirais
|
CA2527024C
(en)
*
|
2003-05-28 |
2012-08-21 |
Paul Anziano |
Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
|
US20050113314A1
(en)
*
|
2003-08-29 |
2005-05-26 |
Fong Benson M. |
Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
|
US20050043391A1
(en)
*
|
2003-07-17 |
2005-02-24 |
Fong Benson M. |
Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
|
US20060089374A1
(en)
*
|
2003-07-17 |
2006-04-27 |
Glenn Cornett |
Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
US20050148534A1
(en)
*
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
GB0322994D0
(en)
*
|
2003-10-01 |
2003-11-05 |
Novartis Ag |
Organic compounds
|
KR20060110872A
(ko)
*
|
2003-10-29 |
2006-10-25 |
소너스파머슈티칼즈인코포레이티드 |
토코페롤 변성 치료제 약물 화합물
|
US20080045559A1
(en)
*
|
2003-10-29 |
2008-02-21 |
Sonus Pharmaceuticals, Inc. |
Tocopherol-modified therapeutic drug compounds
|
US7820839B2
(en)
*
|
2003-10-30 |
2010-10-26 |
The Research Foundation Of State University Of New York |
Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
|
GB0326180D0
(en)
*
|
2003-11-11 |
2003-12-17 |
Leuven K U Res & Dev |
Biocompatible coating of medical devices
|
SV2006002010A
(es)
|
2004-02-13 |
2006-08-23 |
Univ Florida State Res Found |
Taxanos sustituidos con esteres de ciclopentilo en c10
|
AR048078A1
(es)
|
2004-03-05 |
2006-03-29 |
Univ Florida State Res Found |
Taxanos con sustituyente lactiloxilo en el c7
|
US20100009928A1
(en)
*
|
2004-03-29 |
2010-01-14 |
Cheng Jin Q |
Compositions including triciribine and taxanes and methods of use thereof
|
US20110008327A1
(en)
|
2004-03-29 |
2011-01-13 |
Cheng Jin Q |
Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
|
US20100009929A1
(en)
|
2004-03-29 |
2010-01-14 |
Cheng Jin Q |
Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
|
US20100028339A1
(en)
|
2004-03-29 |
2010-02-04 |
Cheng Jin Q |
Compositions including triciribine and trastuzumab and methods of use thereof
|
LT2574341T
(lt)
|
2004-03-29 |
2017-09-11 |
University Of South Florida |
Navikų ir vėžio efektyvus gydymas triciribino fosfatu
|
US20100173864A1
(en)
|
2004-03-29 |
2010-07-08 |
Cheng Jin Q |
Compositions including triciribine and one or more platinum compounds and methods of use thereof
|
GB0413730D0
(en)
*
|
2004-06-18 |
2004-07-21 |
Tillotts Pharma Ag |
A pharmaceutical composition and its use
|
GB0413729D0
(en)
*
|
2004-06-18 |
2004-07-21 |
Tillotts Pharma Ag |
A pharmaceutical composition and its use
|
RS51799B
(en)
|
2004-07-27 |
2011-12-31 |
Gilead Sciences Inc. |
NUCLEOSIDE-PHOSPHONATE CONJUGATES AS HIV AGENTS
|
US20060154959A1
(en)
*
|
2005-01-13 |
2006-07-13 |
Navitas Pharma |
Combination therapies of cicletanine and carvedilol
|
PL1791904T3
(pl)
*
|
2004-09-24 |
2015-02-27 |
Univ Maryland |
Sposób leczenia zatrucia związkami fosforoorganicznymi
|
US9132135B2
(en)
*
|
2004-09-24 |
2015-09-15 |
University Of Maryland, Baltimore |
Method of treating organophosphorous poisoning
|
US20060122127A1
(en)
*
|
2004-11-17 |
2006-06-08 |
Cypress Bioscience, Inc. |
Methods for reducing the side effects associated with mirtzapine treatment
|
US20070141174A1
(en)
*
|
2005-01-13 |
2007-06-21 |
Navitas Pharma, Inc. |
Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
|
US20080096915A1
(en)
*
|
2005-01-13 |
2008-04-24 |
Greenberg Traurig LLP |
Compositions for the treatment of metabolic disorders
|
CA2596755C
(en)
|
2005-02-09 |
2014-09-09 |
Paul Q. Anziano |
Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
|
AU2006220626A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Sound Pharmaceuticals Incorporated |
Methods and compositions for treating cancer
|
US20060216767A1
(en)
*
|
2005-03-22 |
2006-09-28 |
Saladax Biomedical Inc. |
Docetaxel immunoassay
|
JP5337479B2
(ja)
|
2005-05-04 |
2013-11-06 |
プロノヴァ・バイオファーマ・ノルゲ・アーエス |
新規化合物
|
AU2006256369B2
(en)
*
|
2005-06-07 |
2012-08-02 |
Bar-Ilan University |
Novel salts of conjugated psychotropic drugs and processes of preparing same
|
US20070105817A1
(en)
*
|
2005-11-09 |
2007-05-10 |
Jim Page |
Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
|
CN1870631B
(zh)
*
|
2005-11-11 |
2010-04-14 |
华为技术有限公司 |
媒体网关的门控方法
|
JP2009515895A
(ja)
*
|
2005-11-14 |
2009-04-16 |
ピーター ディー. ウインチ |
注射用薬物および薬学的に許容されるその塩の着色溶液
|
CA2632149C
(en)
*
|
2005-12-01 |
2011-11-15 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
CN103214484B
(zh)
|
2005-12-13 |
2016-07-06 |
因塞特控股公司 |
作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
|
CZ300305B6
(cs)
*
|
2005-12-20 |
2009-04-15 |
Heaton, A. S. |
Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
|
MX2008013034A
(es)
*
|
2006-04-13 |
2008-10-17 |
Actelion Pharmaceuticals Ltd |
Antagonistas del receptor de endotelina para etapas tempranas de fibrosis pulmonar idiopatica.
|
EP2015632B1
(en)
*
|
2006-04-19 |
2015-12-02 |
Mist Pharmaceuticals, LLC |
Stable hydroalcoholic oral spray formulations and methods
|
CN101442994B
(zh)
*
|
2006-05-16 |
2013-03-06 |
吉里德科学公司 |
用于治疗恶性血液病的方法和组合物
|
FR2902659A1
(fr)
|
2006-06-23 |
2007-12-28 |
Pierre Fabre Medicament Sa |
Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
|
KR20090048462A
(ko)
|
2006-07-17 |
2009-05-13 |
라모트 앳 텔-아비브 유니버시티 리미티드 |
통증완화용 gaba 접합체
|
WO2008014456A2
(en)
*
|
2006-07-28 |
2008-01-31 |
Collegium Pharmaceutical, Inc. |
Combination therapy for otitis with antiseptic and ph adjustment
|
WO2008021242A2
(en)
*
|
2006-08-10 |
2008-02-21 |
The Research Foundation Of State University Of New York |
Fluorotaxoid-fatty acid conjugates and pharmaceutical compositions thereof
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
US8399516B2
(en)
|
2006-11-01 |
2013-03-19 |
Pronova Biopharma Norge As |
Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR)
|
MX2009006528A
(es)
*
|
2006-12-21 |
2009-06-26 |
Pfizer Prod Inc |
Sal de succinato de la 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol- 3-il)fenoxi)metil)quinolina.
|
CA2673049C
(en)
*
|
2006-12-22 |
2016-02-23 |
Novadel Pharma Inc. |
Stable anti-nausea oral spray formulations and methods
|
JP2010514841A
(ja)
*
|
2007-01-03 |
2010-05-06 |
グレン ブイ. コルネット, |
肺疾患および心疾患の処置におけるシクレタニンおよびpkc阻害剤
|
CL2008000070A1
(es)
*
|
2007-01-17 |
2008-07-25 |
Lg Life Sciences Ltd |
Monosal del acido maleico (3-[({1-[(2-amino-9h-purin-9-il)metil]ciclopropil}oxi)metil]-8,8-dimetil-3,7-dioxo-2,4,6-trioxa-3 lambda 5-fosfanon-1-il-pivalato; composicion farmaceutica que comprende a dicha monosal; y uso para el tratamiento del virus h
|
US20100093749A1
(en)
*
|
2007-03-09 |
2010-04-15 |
Novartis Ag |
Compounds
|
US9220837B2
(en)
*
|
2007-03-19 |
2015-12-29 |
Insuline Medical Ltd. |
Method and device for drug delivery
|
CN101801346A
(zh)
*
|
2007-05-10 |
2010-08-11 |
诺瓦德尔药品公司 |
抗失眠症组合物及方法
|
US20090099062A1
(en)
*
|
2007-05-31 |
2009-04-16 |
Ethan Lee |
Pyrvinium For The Treatment of Cancer
|
EP2740731B1
(en)
*
|
2007-06-13 |
2016-03-23 |
Incyte Holdings Corporation |
Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
US8067632B2
(en)
|
2007-07-26 |
2011-11-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Process to produce prostratin and structural or functional analogs thereof
|
NZ583824A
(en)
*
|
2007-09-26 |
2012-06-29 |
Sinai School Medicine |
Azacytidine analogues and uses thereof
|
US7985325B2
(en)
*
|
2007-10-30 |
2011-07-26 |
Novellus Systems, Inc. |
Closed contact electroplating cup assembly
|
CN101328159B
(zh)
*
|
2007-11-05 |
2011-12-21 |
孙汉翔 |
紫杉烷前体抗癌药及其药物组合物和用途
|
CN101918418A
(zh)
*
|
2007-12-12 |
2010-12-15 |
阿尔迪默菲克斯技术有限责任公司 |
替诺福韦地索普西的固体形式
|
PE20091156A1
(es)
*
|
2007-12-17 |
2009-09-03 |
Astrazeneca Ab |
Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
|
EP2252578B1
(en)
|
2008-02-11 |
2012-08-01 |
Ramot at Tel Aviv University Ltd. |
Conjugates for treating neurodegenerative diseases and disorders
|
EP2276755A4
(en)
|
2008-03-31 |
2011-05-04 |
Univ Florida State Res Found |
C (10) -ETHYESTER- AND C (10) -CYCLOPROPYLESTER-SUBSTITUTED TAXANES
|
AU2009234127B2
(en)
*
|
2008-04-10 |
2015-04-30 |
Abraxis Bioscience, Llc |
Compositions of hydrophobic taxane derivatives and uses thereof
|
JP5739802B2
(ja)
*
|
2008-05-13 |
2015-06-24 |
アストラゼネカ アクチボラグ |
4−(3−クロロ−2−フルオロアニリノ)−7−メトキシ−6−{[1−(n−メチルカルバモイルメチル)ピペリジン−4−イル]オキシ}キナゾリンのフマル酸塩
|
WO2009148623A2
(en)
|
2008-06-05 |
2009-12-10 |
Stc.Unm |
Methods and related compositions for the treatment of cancer
|
US9085527B2
(en)
|
2008-07-08 |
2015-07-21 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid acylated salicylates and their uses
|
AP3347A
(en)
|
2008-07-08 |
2015-07-31 |
Gilead Sciences Inc |
Salts of HIV inhibitor compounds
|
CN102149673B
(zh)
|
2008-07-08 |
2014-07-09 |
凯特贝希制药公司 |
脂肪酸乙酰化的水杨酸酯及其用途
|
US9145396B2
(en)
|
2008-12-01 |
2015-09-29 |
Targacept, Inc. |
Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
|
CA3090738C
(en)
*
|
2008-12-01 |
2023-06-13 |
Oyster Point Pharma, Inc. |
Synthesis and salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
|
JP2012512165A
(ja)
*
|
2008-12-11 |
2012-05-31 |
バイオヴィスタ,インコーポレイテッド |
四環系ピラジノインドールを用いた多発性硬化症の治療方法
|
AR074694A1
(es)
*
|
2008-12-18 |
2011-02-02 |
Novartis Ag |
Sal de hemifumarato del acido 1-(4-{1-[(e)-4-ciclohexil-3-trifluoro-metil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxilico, y otras formas cristalinas de la misma.
|
US9034389B2
(en)
|
2009-03-11 |
2015-05-19 |
Stable Solutions Llc |
Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
|
US8993625B2
(en)
*
|
2009-03-11 |
2015-03-31 |
Stable Solutions Llc |
Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
|
BRPI1014160A2
(pt)
*
|
2009-04-10 |
2015-08-25 |
Abraxis Bioscience Llc |
Formulações de nanopartículas e aplicações das mesmas
|
US20100298255A1
(en)
*
|
2009-05-19 |
2010-11-25 |
Vivia Biotech S.L. |
Methods for providing personalized medicine test ex vivo for hematological neoplasms
|
HUE046493T2
(hu)
|
2009-05-22 |
2020-03-30 |
Incyte Holdings Corp |
3-[4-(7H-Pirrolo[2,3-d]pirimidin-4-il)-lH-pirazol-l-il]oktán- vagy heptán-nitril JAK inhibitorokként
|
TW201113285A
(en)
*
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
MX2012006566A
(es)
|
2009-12-09 |
2012-11-29 |
Univ Ramot |
Metodo para mejorar las funciones cognoscitivas.
|
MY160249A
(en)
|
2010-01-08 |
2017-02-28 |
Catabasis Pharmaceuticals Inc |
Fatty acid fumarate derivatives and their uses
|
MY175156A
(en)
|
2010-03-10 |
2020-06-11 |
Incyte Corp |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
TWI499421B
(zh)
|
2010-05-21 |
2015-09-11 |
Incyte Corp |
Jak抑制劑的局部製劑
|
US8916610B2
(en)
|
2010-09-22 |
2014-12-23 |
Ramot At Tel-Aviv University Ltd. |
Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
|
JP5917544B2
(ja)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
|
CN103415515B
(zh)
|
2010-11-19 |
2015-08-26 |
因塞特公司 |
作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
|
US20120178813A1
(en)
|
2011-01-12 |
2012-07-12 |
Thetis Pharmaceuticals Llc |
Lipid-lowering antidiabetic agent
|
WO2012154554A1
(en)
*
|
2011-05-06 |
2012-11-15 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid triterpene derivatives and their uses
|
AU2012273164B2
(en)
|
2011-06-20 |
2015-05-28 |
Incyte Holdings Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
|
CN102952138B
(zh)
*
|
2011-08-17 |
2016-07-06 |
上海特化医药科技有限公司 |
一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
CA2834327C
(en)
|
2011-09-19 |
2017-05-30 |
Orexo Ab |
New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
|
AU2013257742A1
(en)
*
|
2012-05-07 |
2014-11-27 |
Cellixbio Private Limited |
Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
US9382187B2
(en)
|
2012-07-10 |
2016-07-05 |
Thetis Pharmaceuticals Llc |
Tri-salt form of metformin
|
US8765811B2
(en)
|
2012-07-10 |
2014-07-01 |
Thetis Pharmaceuticals Llc |
Tri-salt form of metformin
|
WO2014078486A1
(en)
|
2012-11-15 |
2014-05-22 |
Incyte Corporation |
Sustained-release dosage forms of ruxolitinib
|
ES2707355T3
(es)
|
2013-03-06 |
2019-04-03 |
Incyte Holdings Corp |
Procesos y productos intermedios para elaborar un inhibidor de JAK
|
CA3155500A1
(en)
|
2013-08-07 |
2015-02-12 |
Incyte Corporation |
Sustained release dosage forms for a jak1 inhibitor
|
US10463684B2
(en)
|
2014-01-29 |
2019-11-05 |
Board Of Regents, The Uneversety Of Texas System |
Nucleobase analogue derivatives and their applications
|
CA2947741A1
(en)
|
2014-05-05 |
2015-11-12 |
Thetis Pharmaceuticals Llc |
Compositions and methods relating to ionic salts of peptides
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
US9242008B2
(en)
|
2014-06-18 |
2016-01-26 |
Thetis Pharmaceuticals Llc |
Mineral amino-acid complexes of fatty acids
|
BR112016029476A2
(pt)
|
2014-06-18 |
2017-08-22 |
Thetis Pharmaceuticals Llc |
complexos de aminoácido mineral de agentes ativos
|
CN104225615B
(zh)
*
|
2014-09-24 |
2017-02-01 |
东南大学 |
一种紫杉醇类磷脂化合物、其药物组合物及应用
|
WO2016198971A1
(en)
*
|
2015-06-08 |
2016-12-15 |
Mohan M Alapati |
Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
|
WO2017160687A1
(en)
*
|
2016-03-15 |
2017-09-21 |
Vitality Biopharma, Inc. |
Methods and compositions for the treatment of demyelinating disorders
|
KR102437682B1
(ko)
|
2016-06-03 |
2022-08-29 |
테티스 파마수티컬스 엘엘씨 |
특화된 사전 해소 매개체의 염에 관한 조성물 및 방법
|
WO2018002673A1
(en)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Novel formulations of angiotensin ii receptor antagonists
|
WO2019027920A1
(en)
|
2017-08-01 |
2019-02-07 |
Gilead Sciences, Inc. |
CRYSTALLINE FORMS OF ETHYL ((S) - (((((2R, 5R) -5- (6-AMINO-9H-PURIN-9-YL) -4-FLUORO-2,5-DIHYDROFURAN-2-YL) OXY ) METHYL) (PHENOXY) PHOSPHORYL) -L-ALANINATE (GS-9131) FOR THE TREATMENT OF VIRAL INFECTIONS
|
AR113922A1
(es)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
|
MA51771B1
(fr)
|
2018-01-30 |
2022-03-31 |
Incyte Corp |
Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)
|
PE20210402A1
(es)
|
2018-03-30 |
2021-03-02 |
Incyte Corp |
Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
|
CN112367989A
(zh)
|
2018-04-17 |
2021-02-12 |
卡都瑞恩医药有限责任公司 |
噻吩并嘧啶的葡甲胺盐
|
US11897928B2
(en)
|
2018-07-18 |
2024-02-13 |
Manzanita Pharmaceuticals, Inc. |
Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
|
WO2020018888A1
(en)
|
2018-07-20 |
2020-01-23 |
The Board Of Regents Of The University Of Oklahoma |
Antimicrobial peptides and methods of use
|
MX2021000977A
(es)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
|
JP2022528699A
(ja)
*
|
2019-03-22 |
2022-06-15 |
インテグレイテッド ナノセラピューティクス インコーポレイテッド |
足場部分から調製した脂質結合体
|
WO2021102258A1
(en)
|
2019-11-22 |
2021-05-27 |
Incyte Corporation |
Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|